Literature DB >> 25620850

Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry.

Shunji Tomatsu1, Francyne Kubaski2, Kazuki Sawamoto3, Robert W Mason3, Eriko Yasuda3, Tsutomu Shimada3, Adriana M Montaño4, Seiji Yamaguchi5, Yasuyuki Suzuki6, Tadao Orii7.   

Abstract

Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by the deficiency of lysosomal enzymes. The enzymes are required to break down glycosaminoglycans (GAGs) that help build bone, cartilage, tendons, corneas, skin and connective tissue. In patients with MPS, a missing enzyme leads to the accumulation of GAGs in the cells, blood, connective tissues, and multiple organs. The consequence is permanent, with progressive cellular damage affecting patients' appearance, physical abilities, organ and system function, and skeletal and mental development. The measurement of each specific GAG in a variety of specimens is required to establish the correlation between GAGs and physiological status of patients and/or prognosis and pathogenesis of the disease and to separate the patients with MPS from the healthy controls. We have developed a highly accurate, sensitive, and cost-effective liquid chromatography tandem mass spectrometry (LC-MS/MS) method for measurements of disaccharides derived from four specific GAGs [chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS)]. Disaccharides were produced by specific enzyme digestion of each GAG, and subsequently, quantified by negative ion mode of multiple reaction monitoring. Subclasses of GAGs with the same molecular weights can be separated by liquid chromatography. We have also developed another GAG assay by high-throughput mass spectrometry (HT-MS/MS). The HT-MS/MS consists of an integrated solid phase extraction robot that binds and de-salts samples from assay plates and directly injects them into a MS/MS detector, reducing sample processing time to within ten seconds. HT-MS/MS consequently yields much faster throughput than conventional LC-MS/MS-based methods; however, the HT-MS/MS system does not use a chromatographic step, and therefore, cannot separate GAGs that have the same molecular weights. Both techniques can be applied to the analysis of dried blood spots, blood, and urine specimens. In this review, we describe the assay methods for GAGs and the application to newborn screening and diagnosis of MPS.

Entities:  

Keywords:  diagnosis; glycosaminoglycans; mucopolysaccharidoses; newborn screening; tandem mass spectrometry

Year:  2014        PMID: 25620850      PMCID: PMC4303184     

Source DB:  PubMed          Journal:  Nihon Masu Sukuriningu Gakkai Shi        ISSN: 0917-3803


  46 in total

1.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

Authors:  A C Crawley; K H Niedzielski; E L Isaac; R C Davey; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.

Authors:  C Vogler; M S Sands; B Levy; N Galvin; E H Birkenmeier; W S Sly
Journal:  Pediatr Res       Date:  1996-06       Impact factor: 3.756

3.  Studies on keratosulfates. Methylation, desulfation, and acid hydrolysis studies on old human rib cartilage keratosulfate.

Authors:  V P Bhavanandan; K Meyer
Journal:  J Biol Chem       Date:  1968-03-10       Impact factor: 5.157

4.  There are two major types of skeletal keratan sulphates.

Authors:  I A Nieduszynski; T N Huckerby; J M Dickenson; G M Brown; G H Tai; H G Morris; S Eady
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

5.  Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.

Authors:  Minke H de Ru; Linda van der Tol; Naomi van Vlies; Brian W Bigger; Carla E M Hollak; Lodewijk Ijlst; Wim Kulik; Henk van Lenthe; Muhammad A Saif; Tom Wagemans; Willem M van der Wal; Ronald J Wanders; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-19       Impact factor: 4.982

6.  Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry.

Authors:  Toshihiro Oguma; Shunji Tomatsu; Osamu Okazaki
Journal:  Biomed Chromatogr       Date:  2007-04       Impact factor: 1.902

7.  Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice.

Authors:  Adriana M Montaño; Hirotaka Oikawa; Shunji Tomatsu; Tatsuo Nishioka; Carole Vogler; Monica A Gutierrez; Toshihiro Oguma; Yun Tan; Jeffrey H Grubb; Vu Chi Dung; Amiko Ohashi; Ken-ichi Miyamoto; Tadao Orii; Yukio Yoneda; William S Sly
Journal:  Mol Genet Metab       Date:  2008-03-21       Impact factor: 4.797

8.  Fetal presentation of Morquio disease type A.

Authors:  M Beck; S Braun; W Coerdt; E Merz; E Young; A C Sewell
Journal:  Prenat Diagn       Date:  1992-12       Impact factor: 3.050

9.  Enzyme replacement therapy in a murine model of Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Amiko Ohashi; Monica A Gutierrez; Hirotaka Oikawa; Toshihiro Oguma; Vu Chi Dung; Tatsuo Nishioka; Tadao Orii; William S Sly
Journal:  Hum Mol Genet       Date:  2007-12-03       Impact factor: 6.150

10.  Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry.

Authors:  Shunji Tomatsu; Adriana M Montaño; Toshihiro Oguma; Vu Chi Dung; Hirotaka Oikawa; Talita Giacomet de Carvalho; María L Gutiérrez; Seiji Yamaguchi; Yasuyuki Suzuki; Masaru Fukushi; Kazuhiro Kida; Mitsuru Kubota; Luis Barrera; Tadao Orii
Journal:  J Inherit Metab Dis       Date:  2010-01-27       Impact factor: 4.982

View more
  11 in total

1.  Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.

Authors:  Min-Ju Chan; Hsuan-Chieh Liao; Michael H Gelb; Chih-Kuang Chuang; Mei-Ying Liu; Hsiao-Jan Chen; Shu-Min Kao; Hsiang-Yu Lin; You-Hsin Huang; Arun Babu Kumar; Naveen Kumar Chennamaneni; Nagendar Pendem; Shuan-Pei Lin; Chuan-Chi Chiang
Journal:  J Pediatr       Date:  2018-11-06       Impact factor: 4.406

2.  Analysis of Total Human Urinary Glycosaminoglycan Disaccharides by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Xiaojun Sun; Lingyun Li; Katherine H Overdier; Lee Anne Ammons; Ivor S Douglas; Clay Cothren Burlew; Fuming Zhang; Eric P Schmidt; Lianli Chi; Robert J Linhardt
Journal:  Anal Chem       Date:  2015-06-02       Impact factor: 6.986

Review 3.  Glycosaminoglycans detection methods: Applications of mass spectrometry.

Authors:  Francyne Kubaski; Harumi Osago; Robert W Mason; Seiji Yamaguchi; Hironori Kobayashi; Mikako Tsuchiya; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-09-28       Impact factor: 4.797

Review 4.  Advances in glycosaminoglycan detection.

Authors:  Shaukat A Khan; Robert W Mason; Hironori Kobayashi; Seiji Yamaguchi; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2020-03-27       Impact factor: 4.797

5.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.

Authors:  Shaukat A Khan; Robert W Mason; Roberto Giugliani; Kenji Orii; Toshiyuki Fukao; Yasuyuki Suzuki; Seiji Yamaguchi; Hironori Kobayashi; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-17       Impact factor: 4.797

6.  Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study.

Authors:  Chih-Kuang Chuang; Hsiang-Yu Lin; Tuan-Jen Wang; Sung-Fa Huang; Shuan-Pei Lin
Journal:  BMJ Open       Date:  2017-07-13       Impact factor: 2.692

7.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

Review 8.  Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Authors:  Rachel Heon-Roberts; Annie L A Nguyen; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

9.  Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses.

Authors:  Tsubasa Oguni; Shunji Tomatsu; Misa Tanaka; Kenji Orii; Toshiyuki Fukao; Jun Watanabe; Seiji Fukuda; Yoshitomo Notsu; Dung Chi Vu; Thi Bich Ngoc Can; Atsushi Nagai; Seiji Yamaguchi; Takeshi Taketani; Michael H Gelb; Hironori Kobayashi
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

10.  Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms.

Authors:  Gustavo M Viana; David A Priestman; Frances M Platt; Shaukat Khan; Shunji Tomatsu; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-02-01       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.